• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

    11/12/24 9:55:14 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GOSS alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 GOSSAMER BIO INC COMMON STOCK Cusip #38341P102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #38341P102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 7,920,439 Item 6: 0 Item 7: 7,935,735 Item 8: 0 Item 9: 7,935,735 Item 11: 3.507% Item 12: HC Cusip #38341P102 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 7,935,735 Item 8: 0 Item 9: 7,935,735 Item 11: 3.507% Item 12: IN Item 1(a). Name of Issuer: GOSSAMER BIO INC Item 1(b). Address of Issuer's Principal Executive Offices: 3013 SCIENCE PARK SAN DIEGO, CA 92121 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 38341P102 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 7,935,735 (b) Percent of Class: 3.507% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 7,935,735 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of GOSSAMER BIO INC. No one other person's interest in the COMMON STOCK of GOSSAMER BIO INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of GOSSAMER BIO INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Get the next $GOSS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GOSS

    DatePrice TargetRatingAnalyst
    6/25/2024$9.00Outperform
    Oppenheimer
    4/5/2024$4.00Outperform
    Wedbush
    7/27/2023$8.00 → $1.25Buy → Neutral
    UBS
    3/7/2023Outperform → Mkt Perform
    Raymond James
    3/1/2023Neutral
    Guggenheim
    12/7/2022Neutral → Underweight
    JP Morgan
    12/7/2022$3.00Outperform → Neutral
    SMBC Nikko
    12/7/2022$18.00 → $2.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $GOSS
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Gossamer Bio Inc.

      DEFA14A - Gossamer Bio, Inc. (0001728117) (Filer)

      4/29/25 4:01:51 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Gossamer Bio Inc.

      DEF 14A - Gossamer Bio, Inc. (0001728117) (Filer)

      4/29/25 4:01:26 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Gossamer Bio Inc.

      S-8 - Gossamer Bio, Inc. (0001728117) (Filer)

      3/13/25 4:03:20 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective May 5, 2025, to three non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 258,750 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan ("2023 Inducement Plan"). The awards were granted as an induceme

      5/7/25 5:30:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

      Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present a poster at the American Thoracic Society (ATS) 2025 International Conference, taking place from May 16th through 21st, in San Francisco, California. Poster Presentation Title: Seralutinib in Pulmonary Arterial Hypertension: Exploring Mechanisms of Reverse Remodeling Versus Vasodilation Poster Number: P920 Session: A76 Finger on the Pulse: Cardiopulmonary Dysfunction in

      5/7/25 4:01:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective April 7, 2025, to one non-executive employee of non-qualified stock option awards to purchase up to an aggregate of 55,000 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan ("2023 Inducement Plan"). The awards were granted as an inducement

      4/8/25 5:30:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Hasnain Faheem bought $250,282 worth of shares (372,000 units at $0.67) (SEC Form 4)

      4 - Gossamer Bio, Inc. (0001728117) (Issuer)

      6/24/24 5:52:18 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COO/CFO Giraudo Bryan bought $59,110 worth of shares (100,000 units at $0.59) (SEC Form 4)

      4 - Gossamer Bio, Inc. (0001728117) (Issuer)

      6/20/24 8:21:38 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Commercial Officer Smith Robert Paul Jr bought $15,050 worth of shares (25,000 units at $0.60) (SEC Form 4)

      4 - Gossamer Bio, Inc. (0001728117) (Issuer)

      6/20/24 8:20:20 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by EVP, Regulatory Affairs Peterson Caryn

      4 - Gossamer Bio, Inc. (0001728117) (Issuer)

      3/6/25 4:09:17 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by EVP, Tech Ops and Admin Christian Waage

      4 - Gossamer Bio, Inc. (0001728117) (Issuer)

      3/6/25 4:08:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Smith Robert Paul Jr

      4 - Gossamer Bio, Inc. (0001728117) (Issuer)

      3/6/25 4:06:46 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

      Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

      6/21/24 3:17:31 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

      SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

      11/12/24 4:40:26 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

      SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

      11/12/24 9:55:14 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

      SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

      8/2/24 6:30:57 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Financials

    Live finance-specific insights

    See more
    • Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

      - PROSERA Phase 3 in PAH on Track for Topline Data Readout in Fourth Quarter of 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Second Half of 2025 - - Seralutinib Receives Orphan Drug Designation for PAH in Japan - - Cash, cash equivalents and marketable securities totaled $295 million at year-end 2024 - Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December

      3/13/25 4:01:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

      - $327 Million in Cash, Cash Equivalents & Marketable Securities, as of September 30, 2024 - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter ended September 30, 2024 and provided a business update. "Looking forward, we expect 2025 to be an exceptionally important year for Gossamer, as we both anticipate Phase 3 PROSERA Study results in PAH and commence our PH-ILD Phase 3 study," said Faheem Hasnain, Co-

      11/7/24 4:03:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

      - $354 Million in Cash, Cash Equivalents & Marketable Securities, as of June 30, 2024 - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the second quarter ended June 30, 2024 and provided a business update. "Between the continued progress made in the enrollment of the Phase 3 PROSERA Study and the transformational collaboration agreement with the Chiesi Group, Gossamer has made great strides in the second quarter to ad

      8/12/24 4:01:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Leadership Updates

    Live Leadership Updates

    See more
    • Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

      - Mr. Smith is a recognized leader in the commercialization of PAH products, most recently leading sotatercept US pre-launch activities at Merck - - Previously, Mr. Smith led US sales operations for Actelion - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of Bob Smith as its Chief Commercial Officer. "We are proud to welcome Bob Smith to the Gossamer team and his 30 years of expertise at this critical time in our company's history," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio.

      12/5/23 7:01:00 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

      Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors. "Today, we are thrilled to announce that Dr. John Quisel has joined the Gossamer team," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio. "Not only is Dr. Quisel a recognized industry leader with a proven track record of success, but he also brings unique strategic insights and experience in PAH, which will be invaluable. We are confident that Dr. Quise

      11/29/23 7:01:00 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

      Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that Rainer Zimmermann, MD, has joined the Company as Vice President of Medical Affairs. Dr. Zimmermann brings more than 23 years of experience within the PAH/PH space, most recently having served as the Global Medical Lead, Medical Affairs, Pulmonary Hypertension, at Johnson & Johnson Innovative Medicine. In this role, he partnered with the development and commercial teams to lead pre-launch and launch activities of several approved PAH products, including Uptravi® (selixpag),

      10/3/23 4:08:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Gossamer Bio with a new price target

      Oppenheimer initiated coverage of Gossamer Bio with a rating of Outperform and set a new price target of $9.00

      6/25/24 7:48:05 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush resumed coverage on Gossamer Bio with a new price target

      Wedbush resumed coverage of Gossamer Bio with a rating of Outperform and set a new price target of $4.00

      4/5/24 7:26:48 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio downgraded by UBS with a new price target

      UBS downgraded Gossamer Bio from Buy to Neutral and set a new price target of $1.25 from $8.00 previously

      7/27/23 9:01:18 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care